277 related articles for article (PubMed ID: 34281355)
1. Resistance to platinum-based cancer drugs: a special focus on epigenetic mechanisms.
Mora Y; Reyes ME; Zanella L; Mora B; Buchegger K; Ili C; Brebi P
Pharmacogenomics; 2021 Aug; 22(12):777-790. PubMed ID: 34281355
[TBL] [Abstract][Full Text] [Related]
2. LncRNA regulation: New frontiers in epigenetic solutions to drug chemoresistance.
Zhou Y; Sun W; Qin Z; Guo S; Kang Y; Zeng S; Yu L
Biochem Pharmacol; 2021 Jul; 189():114228. PubMed ID: 32976832
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.
Soto JA; Rodríguez-Antolín C; Vera O; Pernía O; Esteban-Rodríguez I; Dolores Diestro M; Benitez J; Sánchez-Cabo F; Alvarez R; De Castro J; Ibanez de Cáceres I
Clin Epigenetics; 2021 Aug; 13(1):167. PubMed ID: 34454589
[TBL] [Abstract][Full Text] [Related]
4. Cancer's epigenetic drugs: where are they in the cancer medicines?
Ghasemi S
Pharmacogenomics J; 2020 Jun; 20(3):367-379. PubMed ID: 31819161
[TBL] [Abstract][Full Text] [Related]
5. The Mechanisms of Current Platinum Anticancer Drug Resistance in the Glioma.
Lu E; Gareev I; Yuan C; Liang Y; Sun J; Chen X; Beylerli O; Sufianov A; Zhao S; Yang G
Curr Pharm Des; 2022; 28(23):1863-1869. PubMed ID: 35674307
[TBL] [Abstract][Full Text] [Related]
6. Preclinical perspectives on the use of platinum compounds in cancer chemotherapy.
Farrell NP
Semin Oncol; 2004 Dec; 31(6 Suppl 14):1-9. PubMed ID: 15726528
[TBL] [Abstract][Full Text] [Related]
7. The bitter side of epigenetics: variability and resistance to chemotherapy.
Hajji N; García-Domínguez DJ; Hontecillas-Prieto L; O'Neill K; de Álava E; Syed N
Epigenomics; 2021 Mar; 13(5):397-403. PubMed ID: 29932342
[TBL] [Abstract][Full Text] [Related]
8. Systematic identification of dysregulated lncRNAs associated with platinum-based chemotherapy response across 11 cancer types.
Zhu Y; Zhao Y; Dong S; Liu L; Tai L; Xu Y
Genomics; 2020 Mar; 112(2):1214-1222. PubMed ID: 31302201
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Targeting of Platinum Resistant Testicular Cancer.
Sonnenburg D; Spinella MJ; Albany C
Curr Cancer Drug Targets; 2016; 16(9):789-795. PubMed ID: 26694252
[TBL] [Abstract][Full Text] [Related]
10. Using Epigenetic Therapy to Overcome Chemotherapy Resistance.
Strauss J; Figg WD
Anticancer Res; 2016 Jan; 36(1):1-4. PubMed ID: 26722021
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
[TBL] [Abstract][Full Text] [Related]
12. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?
Perez-Plasencia C; Duenas-Gonzalez A
Mol Cancer; 2006 Jul; 5():27. PubMed ID: 16831224
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNAs in cancer drug resistance development.
Majidinia M; Yousefi B
DNA Repair (Amst); 2016 Sep; 45():25-33. PubMed ID: 27427176
[TBL] [Abstract][Full Text] [Related]
14. Epigenetics in cancer stem cells.
Toh TB; Lim JJ; Chow EK
Mol Cancer; 2017 Feb; 16(1):29. PubMed ID: 28148257
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic reprogramming and potential application of epigenetic-modifying drugs in acquired chemotherapeutic resistance.
Ponnusamy L; Mahalingaiah PKS; Singh KP
Adv Clin Chem; 2020; 94():219-259. PubMed ID: 31952572
[TBL] [Abstract][Full Text] [Related]
16. Epigenetics and oncology.
Mummaneni P; Shord SS
Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
[TBL] [Abstract][Full Text] [Related]
17. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy.
Chen F; Shi Y; Zhang J; Liu Q
Curr Drug Targets; 2020; 21(11):1084-1098. PubMed ID: 32410563
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic targeting in pancreatic cancer.
van Kampen JG; Marijnissen-van Zanten MA; Simmer F; van der Graaf WT; Ligtenberg MJ; Nagtegaal ID
Cancer Treat Rev; 2014 Jun; 40(5):656-64. PubMed ID: 24433955
[TBL] [Abstract][Full Text] [Related]
20. Role of epigenetics-microRNA axis in drug resistance of multiple myeloma.
Rastgoo N; Abdi J; Hou J; Chang H
J Hematol Oncol; 2017 Jun; 10(1):121. PubMed ID: 28623912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
